A small clinical trial confirmed these findings, showing that exenatide, another GLP-1 agonist, significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, greatly improving headache symptoms
The effects of ER once-weekly have been compared to exenatide twice-daily and overall ER was more effective at improving glycemic control and caused less gastrointestinal side-effects although both compounds caused a similar degree of weight loss (Drucker et al., The efficacy of once-weekly ER (2 mg) was compared to that of once-daily liraglutide (1.8 mg) in a 26-week trial in T2DM patients (Buse et al., DPP-4 inhibitors The DPP-4 inhibitors mediate their action by inhibiting the enzyme DPP-4, which prevents the breakdown of GLP-1 and thereby increases endogenous GLP-1 levels
MIDDLE EAST GLUTATHIONE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION) TABLE 343
Massier L, Chakaroun R, Tabei S, Crane A, Didt KD, Fallmann J, von Bergen M, Haange SB, Heyne H, Stumvoll M, Gericke M, Dietrich A, Blher M, Musat N, Kovacs P
Ferrootosis: death by lipid peroxidation